VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
FirstWord Pharma,
Analysis shows a CA-125 responseofat least 58% in the VB-111 treatment arm Published online in Gynecologic Oncology TEL AVIV…